Abstract:BACKGROUND:Recent genomic sequencing efforts have identified a number of recurrent mutations in myelodysplastic syndromes (MDS) that may contribute to disease progression and overall survival, including mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2).METHODS:Pretreatment bone marrow (BM) samples were acquired from mononuclear cells in 146 adult patients with de novo MDS from January 2006 to June 2013. Polymerase chain reaction (PCR) and direct sequencing were performed on exon 4 of IDH1/2 genes and mutation status was correlated with overall survival (OS) and leukemia-free survival (LFS). We then performed a meta-analysis combining previously published and current studies to explore the effect of IDH mutations on OS and LFS in MDS.RESULTS:In our study, somatic mutations of either IDH gene were discovered in 11 MDS patients (7.53%) and were significantly correlated with poorer OS (P = 0.007). IDH mutations were specifically associated with a poorer OS in the intermediate-1 risk group by the International Prognostic Scoring System (IPSS) (P = 0.039). In addition, we discovered decitabine achieved a better therapeutic effect compared to other treatments in IDH mutation-positive patients (P = 0.023). We identified six previous studies of IDH mutations in MDS. A meta-analysis of these studies included 111 MDS patients IDH mutations and 1671 MDS patients with wild-type IDH1/2. The hazard ratios (HRs) of OS and LFS for patients with IDH mutations were 1.62 (95% CI, 1.27-2.09) and 2.21 (95% CI, 1.48-3.30), respectively.CONCLUSION:The results from our study and the meta-analysis provide firm evidence that IDH mutations are significantly associated with poorer clinical outcomes in MDS. Identification of IDH mutations may be pivotal for better risk stratification in MDS patients and improving IPSS score. Additionally, hypomethylating agents may be an effective treatment option for MDS patients with IDH mutations.

Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises-a narrative review

Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: a Retrospective Cohort Study and Meta-Analysis.

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors

IDH inhibition in gliomas: from preclinical models to clinical trials

Advances in the treatment of IDH-mutant gliomas

Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma

Systematic Review of Epigenetic Therapies for Treatment of IDH-mutant Glioma

Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside

To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma

Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma

The Role of Mutant IDH Inhibitors in the Treatment of Glioma

Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors—Recent Advances, Challenges and Future Prospects

Multidisciplinary Management of Isocitrate Dehydrogenase–Mutated Gliomas in a Contemporary Molecularly Defined Era

Comprehensive Exploration of Isocitrate Dehydrogenase (IDH) Mutations: Tumorigenesis, Drug Discovery, and Covalent Inhibitor Advances

P89.07 A Large-Scale Survey of IDH1/2 Mutation in Chinese Patients with NSCLC

Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (midh1/2): an Update and Perspective.

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications

The Regulatory Mechanisms and Inhibitors of Isocitrate Dehydrogenase 1 in Cancer